Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Evofem Biosciences earns FDA approval for its first drug: Phexxi

Phexxi: UIC’s 4th FDA approved drug on the market.

Phexxi TM a non-hormonal vaginal gel, has recently earned FDA approval for use as a female contraceptive. Phexxi was created out of a collaboration between University of Illinois, UIC College of Pharmacy professor, Dr. Donald Waller, and Rush University Medical Center professor Dr. Lourens Zaneveld.

This new form of contraceptive, licensed by Evofem Biosciences, is unlike any prior contraceptive in that it provides women more control over their reproductive health and provides protection against chlamydia and gonorrhea in addition to protection against pregnancy without the use of hormones.

This is a great achievement for Evofem Biosciences and UIC. Phexxi TM is UIC’s 4th FDA approved drug on the market.


For more information on this story:

For more information about Evofem Biosciences and their clinical pipeline: